OCS Stock — Price, Charts & Analysis

Oculis Holding AG (OCS) has no trailing P/E shown and a forward P/E of -6.44x. This places OCS in not enough valuation data territory based on the valuation data currently available on Worldtickers.

OCS trades with -6.44x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether OCS looks overvalued or undervalued.

OCS's P/E of -6.44x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

OCS's trailing EPS is -$1.70 and forward EPS is -$2.06.

EPS, or earnings per share, shows how much profit Oculis Holding AG generated for each share. OCS's trailing EPS is -$1.70, and investors usually prefer EPS that is positive and growing over time.

Oculis Holding AG has a market cap of $724.92M, making OCS a small-cap stock based on the current market value shown on Worldtickers.

OCS's latest stock price on Worldtickers is $13.06. The latest move is -$0.09 or -0.65%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

OCS's quote includes a latest price of $13.06. The market open is $13.17. Previous close is $13.14. The intraday range is $13.03 to $13.27.

OCS is down in the latest quote, with a move of -$0.09 or -0.65%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

OCS generated $1.17M in trailing revenue. Revenue growth is 18.80%, which helps show whether demand is expanding or slowing.

OCS's revenue growth is 18.80%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

No, OCS does not show positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is -$79.19M.

Gross margin is 0.00%. Margins show how efficiently Oculis Holding AG turns revenue into profit.

Oculis Holding AG carries $2.54M and holds $228.32M in cash.

OCS holds $228.32M on its balance sheet.

OCS's book value per share is $4.03.

Institutions hold 47.56% of OCS shares. Insiders hold 3.53% of shares. Ownership mix helps investors understand how much of Oculis Holding AG is held by professional investors and company insiders.

OCS has 55.53M shares outstanding. Float shares are 52.41M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for OCS, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for OCS is -$2.06. Revenue growth is 18.80%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

OCS's trailing EPS is -$1.70. Forward EPS is -$2.06. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

OCS is in the Healthcare sector. Its earnings multiple is -6.44x. Its latest displayed growth metric is 18.80%. Compare these figures with sector peers before deciding whether Oculis Holding AG is stronger or weaker than average.

OCS trades at $13.06. The stock trades at -6.44x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Oculis Holding AG's fundamentals.

OCS risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.23, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

OCS should be compared with companies in Biotechnology. Its earnings multiple is -6.44x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Oculis Holding AG (OCS) operates in Healthcare, specifically Biotechnology. Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotec

OCS trades on NasdaqGM. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

OCS stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Oculis Holding AG's official website listed on Worldtickers is oculis.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Oculis Holding AG employs about 60 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Oculis Holding AG is headquartered in Zug, Switzerland. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

OCS is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

OCS has traded between $10.52 and $34.48 over the past 52 weeks. At $13.06, it is 62.13% below the high and 24.10% above the low. The 52-week range helps gauge long-term price momentum.

OCS is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. Its 50-day moving average is $12.35 and its 200-day moving average is $21.38.

OCS's RSI is 53.20. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

OCS's latest RSI reading is 53.20, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for OCS is near $10.73. Key resistance is near $13.70. Breaks above resistance or below support can change the short-term technical setup.

OCS's nearest reported support level is $10.73. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

OCS's nearest reported resistance level is $13.70. A breakout above resistance can improve momentum, especially when volume confirms the move.

OCS trades about 648K shares daily on average. The latest displayed volume is 18.93K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

OCS's MACD is 0.19, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

OCS is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. RSI is 53.20 (neutral). MACD is bullish. Nearest support is around $10.73. Resistance is around $13.70. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $12.33 (5.41% from price). MA50 is $12.35 (5.23% from price). MA200 is $21.38 (-39.21% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. OCS's MA20 is $12.33. MA50 is $12.35. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

OCS's pivot is near $13.24. Support is near $10.73. Resistance is near $13.70. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for OCS is near $12.52. The next upper resistance zone is near $13.70. These levels help define risk and possible follow-through zones after a breakout or breakdown.

OCS's Bollinger range is roughly $10.68 to $13.99. Band width is near 26.83%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

OCS's ATR-based typical daily range is about 4.61%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 18.93K shares. Average volume is about 648K shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

OCS's all-time high shown on Worldtickers is $34.48. Its all-time low is $6.26. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

OCS has a beta of 0.23, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.